MGC Pharmaceuticals granted Euro license

Company News

by Rachael Jones

Medical cannabis developer MGC Pharmaceuticals (ASX:MXC) has secured a Manufacturing License for its European GMP cannabis production facility.

The Company can immediately start production under this licence for pharmaceutical grade products.

The first product to be released for patients from this pipeline is CannEpil™, a phytocannabinoid-based medication for the treatment of refractory epilepsy, which will soon be available in Australia.

These will be distributed into the global market and target the increasing demand for such products.

Shares in MGC Pharmaceuticals (ASX:MXC) up 7.94 per cent to 7c. 

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.